{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:27:05Z","timestamp":1793820425999,"version":"4.6.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":105,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Andremacon Srl"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma is the most aggressive primary brain tumor, and, despite intensive studies, remains one of the most fatal malignancy in adult humans. Among multiple onco-promoters produced by glioblastoma cells, erythropoietin was found. However, the presence\/function of Epo alternatively spliced variants in cancer remains unexplored. Here, we investigated the expression and role of Epo-variants in glioblastoma, and the therapeutic potential of their targeting through a novel monoclonal antibody (mAb).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcripts and protein levels of Epo-variants in a cohort of human brain tumors were evaluated by RT-PCR, ELISA, and immunohistochemistry. Monoclonal antibodies targeting Epo-Vs were prepared and functionally selected by assaying proliferation, migration, stemness, and angiogenesis in glioblastoma patient-derived cells. Antibody affinity for Epo\/Epo-variant was determined by SPR. In vivo toxicity and therapeutic efficacy of the lead antibody were evaluated in GBM mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found a significant overexpression of Epo-variant transcripts in tissues and cells from GBM patients. After functional selection of newly-produced antibodies, we identified AND-C4 as the lead one for its potent anti-tumoral properties, absence of anti-erythropoietic effects and of toxicity on human brain cells. AND-C4 exhibited high affinity for the Epo-variant EV-3. We demonstrated that EV-3 was efficiently produced and secreted by glioblastoma cells, particularly by stem cells. EV-3 exerted tumorigenic, angiogenic and immunomodulatory properties, and AND-C4 was effective in antagonizing all these actions. In vivo studies in rodent glioblastoma models revealed that AND-C4 selectively bound to tumor tissue and exhibited significant efficacy on tumor growth and animal survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study represents the first evidence on the presence, origin and pro-tumoral activity of EV-3 in human glioblastoma. Moreover, in vitro and in vivo results revealed AND-C4 as novel and promising anti-glioblastoma immunotherapeutic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03620-3","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T02:15:34Z","timestamp":1766715334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Stefania Elena","family":"Navone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Guarnaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Rizzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Campanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Andrea","family":"Alotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Rosa","family":"Miozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Barilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-8226","authenticated-orcid":false,"given":"Laura","family":"Riboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3620_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"3620_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro Oncol. 2023;25:iv1\u201399.","journal-title":"Neuro Oncol"},{"key":"3620_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"3620_CR4","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I. Epidemiology of glioblastoma Multiforme-Literature review. Cancers. 2022;14:2412.","journal-title":"Cancers"},{"key":"3620_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41582-018-0025-8","volume":"14","author":"ML Broekman","year":"2018","unstructured":"Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018;14:482\u201395.","journal-title":"Nat Rev Neurol"},{"key":"3620_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s10495-025-02123-y","volume":"30","author":"N Ghosh","year":"2025","unstructured":"Ghosh N, Chatterjee D, Datta A. Tumor heterogeneity and resistance in glioblastoma: the role of stem cells. Apoptosis. 2025;30:1695\u2013729.","journal-title":"Apoptosis"},{"key":"3620_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/cells10030607","volume":"10","author":"ECF Yeo","year":"2021","unstructured":"Yeo ECF, Brown MP, Gargett T, Ebert LM. The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cells. 2021;10:607.","journal-title":"Cells"},{"key":"3620_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1101\/gad.324301.119","volume":"33","author":"RC Gimple","year":"2019","unstructured":"Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019;33:591\u2013609.","journal-title":"Genes Dev"},{"key":"3620_CR9","first-page":"vdad009","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol Adv. 2023;5:vdad009.","journal-title":"Neurooncol Adv"},{"key":"3620_CR10","doi-asserted-by":"publisher","first-page":"9881","DOI":"10.3390\/cimb46090588","volume":"46","author":"LG Tataranu","year":"2024","unstructured":"Tataranu LG, Turliuc S, Kamel A, Rizea RE, Dricu A, Staicu GA, Baloi SC, Rodriguez SMB, Manole AIM. Glioblastoma tumor microenvironment: an important modulator for tumoral progression and therapy resistance. Curr Issues Mol Biol. 2024;46:9881\u201394.","journal-title":"Curr Issues Mol Biol"},{"key":"3620_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.molmed.2025.01.014","volume":"9","author":"SD Robinson","year":"2025","unstructured":"Robinson SD, Filippopoulou C, Besta S, Samuels M, Betr\u00e1n AL, Abu Ajamieh M, Vella V, Jones W, Giamas G. Spatial biology - unravelling complexity within the glioblastoma microenvironment. Trends Mol Med. 2025;9:846\u201359.","journal-title":"Trends Mol Med"},{"key":"3620_CR12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41467-019-09853-z","volume":"10","author":"A Dirkse","year":"2019","unstructured":"Dirkse A, Golebiewska A, Buder T, Nazarov PV, Muller A, Poovathingal S, Brons NHC, Leite S, Sauvageot N, Sarkisjan D, Seyfrid M, Fritah S, Stieber D, Michelucci A, Hertel F, Herold-Mende C, Azuaje F, Skupin A, Bjerkvig R, Deutsch A, Voss-B\u00f6hme A, Niclou SP. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun. 2019;10:1787.","journal-title":"Nat Commun"},{"key":"3620_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41568-022-00486-x","volume":"22","author":"RC Gimple","year":"2022","unstructured":"Gimple RC, Yang K, Halbert ME, Agnihotri S, Rich JN. Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. Nat Rev Cancer. 2022;22:497\u2013514.","journal-title":"Nat Rev Cancer"},{"key":"3620_CR14","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","volume":"42","author":"D Eisenbarth","year":"2023","unstructured":"Eisenbarth D, Wang YA. Glioblastoma heterogeneity at single cell resolution. Oncogene. 2023;42:2155\u201365.","journal-title":"Oncogene"},{"key":"3620_CR15","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.3390\/ijms21155278","volume":"21","author":"J Vieira de Castro","year":"2020","unstructured":"Vieira de Castro J, Gon\u00e7alves CS, Hormigo A, Costa BM. Exploiting the complexities of glioblastoma stem cells: insights for cancer initiation and therapeutic targeting. Int J Mol Sci. 2020;21:5278.","journal-title":"Int J Mol Sci"},{"key":"3620_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12987-022-00333-z","volume":"19","author":"D Dahlberg","year":"2022","unstructured":"Dahlberg D, Rummel J, Distante S, De Souza GA, Stensland ME, Mariussen E, Rootwelt H, Voie \u00d8, Hassel B. Glioblastoma microenvironment contains multiple hormonal and non-hormonal growth-stimulating factors. Fluids Barriers CNS. 2022;19:45.","journal-title":"Fluids Barriers CNS"},{"key":"3620_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1084\/jem.20131189","volume":"211","author":"A Grover","year":"2014","unstructured":"Grover A, Mancini E, Moore S, Mead AJ, Atkinson D, Rasmussen KD, O\u2019Carroll D, Jacobsen SE, Nerlov C. Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate. J Exp Med. 2014;211:181\u20138.","journal-title":"J Exp Med"},{"key":"3620_CR18","doi-asserted-by":"crossref","unstructured":"Bhoopalan SV, Huang LJ, Weiss MJ. Erythropoietin regulation of red blood cell production: from bench to bedside and back. F1000 Re.s 2020;9:1153.","DOI":"10.12688\/f1000research.26648.1"},{"key":"3620_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000356193","volume":"40","author":"W Jelkmann","year":"2013","unstructured":"Jelkmann W. Physiology and Pharmacology of erythropoietin. Transfus Med Hemother. 2013;40:302\u20139.","journal-title":"Transfus Med Hemother"},{"key":"3620_CR20","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3389\/fphys.2019.01534","volume":"10","author":"S Suresh","year":"2020","unstructured":"Suresh S, Rajvanshi PK, Noguchi CT. The many facets of erythropoietin physiologic and metabolic response. Front Physiol. 2020;10:1534.","journal-title":"Front Physiol"},{"key":"3620_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/jcm7020024","volume":"7","author":"D Ostrowski","year":"2018","unstructured":"Ostrowski D, Heinrich R. Alternative erythropoietin receptors in the nervous system. J Clin Med. 2018;7:24.","journal-title":"J Clin Med"},{"key":"3620_CR22","doi-asserted-by":"publisher","first-page":"349823","DOI":"10.3390\/ijms26083498","volume":"26","author":"C Liongue","year":"2025","unstructured":"Liongue C, Ward AC. Cytokine receptor-like factor 3 (CRLF3) and its emerging roles in neurobiology, hematopoiesis and related human diseases. Int J Mol Sci. 2025;26:349823.","journal-title":"Int J Mol Sci"},{"key":"3620_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41580-022-00545-z","volume":"24","author":"LE Marasco","year":"2023","unstructured":"Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat Rev Mol Cell Biol. 2023;24:242\u201354.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3620_CR24","doi-asserted-by":"publisher","first-page":"e70369","DOI":"10.1002\/ctm2.70369","volume":"15","author":"Z Guo","year":"2025","unstructured":"Guo Z, Zhang X, Li Y, Chen Y, Xu Y. Splicing to keep splicing: A feedback system for cellular homeostasis and state transition. Clin Transl Med. 2025;15:e70369.","journal-title":"Clin Transl Med"},{"key":"3620_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-021-08681-z","volume":"21","author":"Y Li","year":"2021","unstructured":"Li Y, Guo D. Genome-wide profiling of alternative splicing in glioblastoma and their clinical value. BMC Cancer. 2021;21:958.","journal-title":"BMC Cancer"},{"key":"3620_CR26","doi-asserted-by":"publisher","first-page":"555632","DOI":"10.3389\/fonc.2020.555632","volume":"10","author":"L Zhao","year":"2021","unstructured":"Zhao L, Zhang J, Liu Z, Wang Y, Xuan S, Zhao P. Comprehensive characterization of alternative mRNA splicing events in glioblastoma: implications for prognosis, molecular subtypes, and immune microenvironment remodeling. Front Oncol. 2021;10:555632.","journal-title":"Front Oncol"},{"key":"3620_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41420-025-02323-0","volume":"11","author":"R Ben Mrid","year":"2025","unstructured":"Ben Mrid R, El Guendouzi S, Mineo M, El Fatimy R. The emerging roles of aberrant alternative splicing in glioma. Cell Death Discov. 2025;11:50.","journal-title":"Cell Death Discov"},{"key":"3620_CR28","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41598-017-03167-0","volume":"7","author":"C Bonnas","year":"2017","unstructured":"Bonnas C, W\u00fcstefeld L, Winkler D, Kronstein-Wiedemann R, Dere E, Specht K, Boxberg M, Tonn T, Ehrenreich H, Stadler H, Sillaber I. EV-3, an endogenous human erythropoietin isoform with distinct functional relevance. Sci Rep. 2017;7:3684.","journal-title":"Sci Rep"},{"key":"3620_CR29","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1345\/aph.1L231","volume":"42","author":"AM Newland","year":"2008","unstructured":"Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother. 2008;42:1865\u201370.","journal-title":"Ann Pharmacother"},{"key":"3620_CR30","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","volume":"373","author":"J Bohlius","year":"2009","unstructured":"Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532\u201342.","journal-title":"Lancet"},{"key":"3620_CR31","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1002\/cncr.25972","volume":"117","author":"M Chavez-MacGregor","year":"2011","unstructured":"Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a surveillance, epidemiology, and end results-medicare study. Cancer. 2011;117:3641\u201336439.","journal-title":"Cancer"},{"key":"3620_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2014.00563","volume":"5","author":"N Debeljak","year":"2014","unstructured":"Debeljak N, Sol\u00e1r P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol. 2014;5:563.","journal-title":"Front Immunol"},{"key":"3620_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/1078-0432.CCR-05-1771","volume":"12","author":"ME Hardee","year":"2006","unstructured":"Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332\u20139.","journal-title":"Clin Cancer Res"},{"key":"3620_CR34","doi-asserted-by":"crossref","unstructured":"Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim Biophys Acta. 2010;180:82-95.32.","DOI":"10.1016\/j.bbcan.2010.04.002"},{"key":"3620_CR35","first-page":"3561","volume":"61","author":"G Acs","year":"2001","unstructured":"Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K. Verma. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561\u20135.","journal-title":"Cancer Res"},{"key":"3620_CR36","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1535-7163.1525.3.12","volume":"3","author":"AI Belenkov","year":"2004","unstructured":"Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S, Chow TY. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther. 2004;3:1525\u201332.","journal-title":"Mol Cancer Ther"},{"key":"3620_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1947601909356352","volume":"1","author":"Y Cao","year":"2010","unstructured":"Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer. 2010;1:50\u201361.","journal-title":"Genes Cancer"},{"key":"3620_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11060-010-0294-6","volume":"102","author":"B Nico","year":"2011","unstructured":"Nico B, Annese T, Guidolin D, Finato N, Crivellato E, Ribatti D. Epo is involved in angiogenesis in human glioma. J Neurooncol. 2011;102:51\u20138.","journal-title":"J Neurooncol"},{"key":"3620_CR39","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.yexcr.2011.06.011","volume":"317","author":"EA P\u00e9r\u00e8s","year":"2011","unstructured":"P\u00e9r\u00e8s EA, Valable S, Guillamo JS, Marteau L, Bernaudin JF, Roussel S, Lechapt-Zalcman E, Bernaudin M, Petit E. Targeting the erythropoietin receptor on glioma cells reduces tumor growth. Exp Cell Res. 2011;317:2321\u201332.","journal-title":"Exp Cell Res"},{"key":"3620_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4103\/njcp.njcp_126_17","volume":"21","author":"S Cevik","year":"2018","unstructured":"Cevik S, Kitis S, Evran S, Akkaya E, Tosuner Z, Hanimoglu H. The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients. Niger J Clin Pract. 2018;21:502\u20136.","journal-title":"Niger J Clin Pract"},{"key":"3620_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.wneu.2019.06.221","volume":"131","author":"F Torregrossa","year":"2019","unstructured":"Torregrossa F, Aguennouz M, La Torre D, Sfacteria A, Grasso G. Role of erythropoietin in cerebral glioma: an innovative target in neuro-oncology. World Neurosurg. 2019;131:346\u201355.","journal-title":"World Neurosurg"},{"key":"3620_CR42","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.2147\/OTT.S210497","volume":"12","author":"Y Wang","year":"2019","unstructured":"Wang Y, Tan X, Li S, Yang S. The total flavonoid of eucommia ulmoides sensitizes human glioblastoma cells to radiotherapy via HIF-\u03b1\/MMP-2 pathway and activates intrinsic apoptosis pathway. Onco Targets Ther. 2019;12:5515\u201324.","journal-title":"Onco Targets Ther"},{"key":"3620_CR43","doi-asserted-by":"crossref","unstructured":"Blau CA. Erythropoietin in cancer: presumption of innocence? Stem Cells. 2007;25:2094\u20137.","DOI":"10.1634\/stemcells.2007-0229"},{"key":"3620_CR44","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1200\/JCO.2007.10.9728","volume":"25","author":"W Jelkmann","year":"2007","unstructured":"Jelkmann W, Laugsch M. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol. 2007;25:1627\u20138.","journal-title":"J Clin Oncol"},{"key":"3620_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2990.2006.00820.x","volume":"33","author":"M Mittelbronn","year":"2007","unstructured":"Mittelbronn M, Capper D, Bunz B, Dietz K, Goeppert B, Ajaaj R, Tabatabai G, Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W, Weller M, Meyermann R, Simon P. De Novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol. 2007;33:299\u2013307.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3620_CR46","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/sj.bjc.6604220","volume":"98","author":"AM Sinclair","year":"2008","unstructured":"Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, Kassner PD, Watson JE, Arnold GE, Nguyen KC, Powers S, Elliott S. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer. 2008;98:1059\u201367.","journal-title":"Br J Cancer"},{"key":"3620_CR47","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1182\/blood-2009-10-248674","volume":"115","author":"S Swift","year":"2010","unstructured":"Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010;115:4254\u201363.","journal-title":"Blood"},{"key":"3620_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3892\/etm.2011.198","volume":"2","author":"J Brunotte","year":"2011","unstructured":"Brunotte J, Bock HC, Bruck W, Hemmerlein B, Strik H. High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma. Exp Ther Med. 2011;2:295\u20139.","journal-title":"Exp Ther Med"},{"key":"3620_CR49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tem.2012.10.007","volume":"24","author":"Y Cao","year":"2013","unstructured":"Cao Y. Erythropoietin in cancer: a dilemma in risk therapy. Trends Endocrinol Metab. 2013;24:190\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"3620_CR50","doi-asserted-by":"publisher","first-page":"e68083","DOI":"10.1371\/journal.pone.0068083","volume":"8","author":"S Elliott","year":"2013","unstructured":"Elliott S, Swift S, Busse L, Scully S, Van G, Rossi J, Johnson C. Epo receptors are not detectable in primary human tumor tissue samples. PLoS ONE. 2013;8:e68083.","journal-title":"PLoS ONE"},{"key":"3620_CR51","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/glia.22718","volume":"62","author":"G Marfia","year":"2014","unstructured":"Marfia G, Campanella R, Navone SE, Di Vito C, Riccitelli E, Abdel Hadi L, Bornati A, de Rezende G, Giussani P, Tringali C, Viani P, Rampini P, Alessandri G, Parati E, Riboni L. Autocrine\/paracrine sphingosine-1- phosphate fuels proliferative and stemness qualities of glioblastoma stem cells. Glia. 2014;62:1968\u201381.","journal-title":"Glia"},{"key":"3620_CR52","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/j.wneu.2018.08.080","volume":"120","author":"SE Navone","year":"2018","unstructured":"Navone SE, Guarnaccia L, Cordiglieri C, Cris\u00e0 FM, Caroli M, Locatelli M, Schisano L, Rampini P, Miozzo M, La Verde N, Miozzo M, La Verde N, Riboni L, Campanella R, Marfia G. Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to Temozolomide, Bevacizumab, and Sunitinib, impairing vascular endothelial growth factor-related signaling. World Neurosurg. 2018;120:e380\u201391.","journal-title":"World Neurosurg"},{"key":"3620_CR53","first-page":"2123","volume":"12","author":"G Tagliabue","year":"1992","unstructured":"Tagliabue G, Citti L, Massazza G, Damia G, Giavazzi R, D\u2019Incalci M. Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts. Anticancer Res. 1992;12:2123\u20135.","journal-title":"Anticancer Res"},{"key":"3620_CR54","doi-asserted-by":"publisher","first-page":"89595","DOI":"10.18632\/oncotarget.19875","volume":"8","author":"AL Iorio","year":"2017","unstructured":"Iorio AL, da Ros M, Genitori L, Lucchesi M, Colelli F, Signorino G, Cardile F, Laffi G, de Martino M, Pisano C, Sardi I. Tumor response of Temozolomide in combination with morphine in a xenograft model of human glioblastoma. Oncotarget. 2017;8:89595\u2013606.","journal-title":"Oncotarget"},{"key":"3620_CR55","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood.V89.2.493","volume":"89","author":"S Elliott","year":"1997","unstructured":"Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. Mapping of the active site of Recombinant human erythropoietin. Blood. 1997;89:493\u2013502.","journal-title":"Blood"},{"key":"3620_CR56","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/2302","volume":"5","author":"JC Cheetham","year":"1998","unstructured":"Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol. 1998;5:861\u20136.","journal-title":"Nat Struct Biol"},{"key":"3620_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells6040045","volume":"6","author":"AR Monteiro","year":"2017","unstructured":"Monteiro AR, Hill R, Pilkington GJ, Madureira PA. The role of hypoxia in glioblastoma invasion. Cells. 2017;6:45.","journal-title":"Cells"},{"key":"3620_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"key":"3620_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jconrel.2018.08.006","volume":"286","author":"NN Kumar","year":"2018","unstructured":"Kumar NN, Lochhead JJ, Pizzo ME, Nehra G, Boroumand S, Greene G, Thorne RG. Delivery of Immunoglobulin G antibodies to the rat nervous system following intranasal administration: distribution, dose-response, and mechanisms of delivery. J Control Release. 2018;286:467\u201384.","journal-title":"J Control Release"},{"key":"3620_CR60","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.radonc.2007.05.003","volume":"83","author":"HM Said","year":"2007","unstructured":"Said HM, Hagemann C, Staab A, Stojic J, K\u00fchnel S, Vince GH, Flentje M, Roosen K, Vordermark D. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398\u2013405.","journal-title":"Radiother Oncol"},{"key":"3620_CR61","doi-asserted-by":"publisher","first-page":"189383","DOI":"10.1016\/j.bbcan.2025.189383","volume":"1880","author":"S Saha","year":"2025","unstructured":"Saha S, Bhat A, Kukal S, Phalak M, Kumar S. Spatial heterogeneity in glioblastoma: decoding the role of perfusion. Biochim Biophys Acta Rev Cancer. 2025;1880:189383.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3620_CR62","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1074\/jbc.M113.500405","volume":"289","author":"J Bagnall","year":"2014","unstructured":"Bagnall J, Leedale J, Taylor SE, Spiller DG, White MR, Sharkey KJ, Bearon RN, S\u00e9e V. Tight control of hypoxia-inducible factor-\u03b1 transient dynamics is essential for cell survival in hypoxia. J Biol Chem. 2014;289:5549\u201364.","journal-title":"J Biol Chem"},{"key":"3620_CR63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00109-015-1276-0","volume":"93","author":"R Depping","year":"2015","unstructured":"Depping R, Jelkmann W, Kosyna FK. Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing. J Mol Med (Berl). 2015;93:599\u2013608.","journal-title":"J Mol Med (Berl)"},{"key":"3620_CR64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-019-0968-4","volume":"18","author":"NT Chee","year":"2019","unstructured":"Chee NT, Lohse I, Brothers SP. mRNA-to-protein translation in hypoxia. Mol Cancer. 2019;18:49.","journal-title":"Mol Cancer"},{"key":"3620_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/ijo.2024.5678","volume":"65","author":"Y Sun","year":"2024","unstructured":"Sun Y, Hu X. Aberrant alternative splicing in cancer: splicing events and their regulatory mechanisms. Int J Oncol. 2024;65:90.","journal-title":"Int J Oncol"},{"key":"3620_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ahg.12550","volume":"88","author":"T Peng","year":"2024","unstructured":"Peng T, Liu Z, Zhang Y, Liu X, Zhao L, Ma Y, Fan J, Song X, Wang L. The systematic identification of survival-related alternative splicing events and splicing factors in glioblastoma. Ann Hum Genet. 2024;88:320\u201335.","journal-title":"Ann Hum Genet"},{"key":"3620_CR67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1015832726054","volume":"58","author":"T Beppu","year":"2002","unstructured":"Beppu T, Kamada K, Yoshida Y, Arai H, Ogasawara K, Ogawa A. Change of oxygen pressure in glioblastoma tissue under various conditions. J Neurooncol. 2002;58:47\u201352.","journal-title":"J Neurooncol"},{"key":"3620_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cell.2007.04.019","volume":"129","author":"B Keith","year":"2007","unstructured":"Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465\u201372.","journal-title":"Cell"},{"key":"3620_CR69","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/cancers15092613","volume":"15","author":"T Shi","year":"2023","unstructured":"Shi T, Zhu J, Zhang X, Mao X. The role of hypoxia and cancer stem cells in development of glioblastoma. Cancers. 2023;15:2613.","journal-title":"Cancers"},{"key":"3620_CR70","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1038\/onc.2009.252","volume":"28","author":"A Soeda","year":"2009","unstructured":"Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009;28:3949\u201359.","journal-title":"Oncogene"},{"key":"3620_CR71","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.yexcr.2018.12.013","volume":"374","author":"T Annese","year":"2019","unstructured":"Annese T, Tamma R, Ruggieri S, Ribatti D. Erythropoietin in tumor angiogenesis. Exp Cell Res. 2019;374:266\u201373.","journal-title":"Exp Cell Res"},{"key":"3620_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-2094-8-32","volume":"8","author":"M Tafani","year":"2011","unstructured":"Tafani M, Di Vito M, Frati A, Pellegrini L, De Santis E, Sette G, Eramo A, Sale P, Mari E, Santoro A, Raco A, Salvati M, De Maria R, Russo MA. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflam. 2011;8:32.","journal-title":"J Neuroinflam"},{"key":"3620_CR73","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","volume":"15","author":"Z Li","year":"2009","unstructured":"Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15:501\u201313.","journal-title":"Cancer Cell"},{"key":"3620_CR74","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 2017;19:887\u201396.","journal-title":"Neuro Oncol"},{"key":"3620_CR75","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/ijms21061932","volume":"21","author":"A Vollmann-Zwerenz","year":"2020","unstructured":"Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA, Hau P. Tumor cell invasion in glioblastoma. Int J Mol Sci. 2020;21:1932.","journal-title":"Int J Mol Sci"},{"key":"3620_CR76","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1016\/j.cell.2022.06.033","volume":"185","author":"KR Taylor","year":"2022","unstructured":"Taylor KR, Monje M. Invasive glioma cells: the malignant pioneers that follow the current. Cell. 2022;185:2846\u20138.","journal-title":"Cell"},{"key":"3620_CR77","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/brainsci7120166","volume":"7","author":"M Lara-Velazquez","year":"2017","unstructured":"Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, Rahmathulla G, Quinones-Hinojosa A. Advances in brain tumor surgery for glioblastoma in adults. Brain Sci. 2017;7:166.","journal-title":"Brain Sci"},{"key":"3620_CR78","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.3390\/cancers16233900","volume":"16","author":"MS Franco","year":"2024","unstructured":"Franco MS, Raulefs S, Schilling D, Combs SE, Schmid TE. Impact of radiation on invasion and migration of glioma in vitro and in vivo. Cancers (Basel). 2024;16:3900.","journal-title":"Cancers (Basel)"},{"key":"3620_CR79","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/jnc.15475","volume":"158","author":"DC Vittori","year":"2021","unstructured":"Vittori DC, Chamorro ME, Hern\u00e1ndez YV, Maltaneri RE, Nesse AB. Erythropoietin and derivatives: potential beneficial effects on the brain. J Neurochem. 2021;158:1032\u201357.","journal-title":"J Neurochem"},{"key":"3620_CR80","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fnmol.2017.00223","volume":"10","author":"N Hahn","year":"2017","unstructured":"Hahn N, Knorr DY, Liebig J, W\u00fcstefeld L, Peters K, B\u00fcscher M, Bucher G, Ehrenreich H, Heinrich R. The insect ortholog of the human orphan cytokine receptor CRLF3 is a neuroprotective erythropoietin receptor. Front Mol Neurosci. 2017;10:223.","journal-title":"Front Mol Neurosci"},{"key":"3620_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/jnc.13967","volume":"141","author":"N Miljus","year":"2017","unstructured":"Miljus N, Massih B, Weis MA, Rison JV, Bonnas CB, Sillaber I, Ehrenreich H, Geurten BR, Heinrich R. Neuroprotection and endocytosis: erythropoietin receptors in insect nervous systems. J Neurochem. 2017;141:63\u201374.","journal-title":"J Neurochem"},{"key":"3620_CR82","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0406491101","volume":"101","author":"M Brines","year":"2004","unstructured":"Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101:14907\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3620_CR83","doi-asserted-by":"publisher","first-page":"1154509","DOI":"10.3389\/fnmol.2023.1154509","volume":"16","author":"DY Knorr","year":"2023","unstructured":"Knorr DY, Rodriguez Polo I, Pies HS, Schwedhelm-Domeyer N, Pauls S, Behr R, Heinrich R. The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor. Front Mol Neurosci. 2023;16:1154509.","journal-title":"Front Mol Neurosci"},{"key":"3620_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pathophys.2012.02.005","volume":"20","author":"LL Ponce","year":"2013","unstructured":"Ponce LL, Navarro JC, Ahmed O, Robertson CS. Erythropoietin neuroprotection with traumatic brain injury. Pathophysiol. 2013;20:31\u20138.","journal-title":"Pathophysiol"},{"key":"3620_CR85","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s11064-021-03242-z","volume":"46","author":"S Hemani","year":"2021","unstructured":"Hemani S, Lane O, Agarwal S, Yu SP, Woodbury A. Systematic review of erythropoietin (EPO) for neuroprotection in human studies. Neurochem Res. 2021;46:732\u20139.","journal-title":"Neurochem Res"},{"key":"3620_CR86","doi-asserted-by":"crossref","unstructured":"Cornelio\u2011Mart\u00ednez S, Casta\u00f1eda\u2011Arellano R. Erythropoietin regulates signaling pathways associated with neuroprotective events. Exp Brain Res. 2022;240:1303-1315.","DOI":"10.1007\/s00221-022-06331-9"},{"key":"3620_CR87","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1161\/STROKEAHA.109.564872","volume":"40","author":"H Ehrenreich","year":"2009","unstructured":"Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, J\u00e4hnig P, Herrmann M, Knauth M, B\u00e4hr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C. EPO stroke trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647\u2013656.","journal-title":"Stroke"},{"key":"3620_CR88","doi-asserted-by":"publisher","first-page":"743926","DOI":"10.3389\/fphar.2022.743926","volume":"13","author":"Y Ma","year":"2022","unstructured":"Ma Y, Zhou Z, Yang GY, Ding J, Wang X. The effect of erythropoietin and its derivatives on ischemic stroke therapy: a comprehensive review. Front Pharmacol. 2022;13:743926.","journal-title":"Front Pharmacol"},{"key":"3620_CR89","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/07388551.2013.793649","volume":"34","author":"AR Costa","year":"2014","unstructured":"Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol. 2014;34:281\u201399.","journal-title":"Crit Rev Biotechnol"},{"key":"3620_CR90","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"3620_CR91","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1146\/annurev-pathol-012414-040438","volume":"10","author":"SR Stowell","year":"2015","unstructured":"Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473\u2013510.","journal-title":"Annu Rev Pathol"},{"key":"3620_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/acschemneuro.7b00271","volume":"9","author":"L Veillon","year":"2018","unstructured":"Veillon L, Fakih C, Abou-El-Hassan H, Kobeissy F, Mechref Y. Glycosylation changes in brain cancer. ACS Chem Neurosci. 2018;9:51\u201372.","journal-title":"ACS Chem Neurosci"},{"key":"3620_CR93","first-page":"381","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS. Brain and other central nervous system tumor statistics. CA Cancer J Clin. 2021;71:381\u2013406.","journal-title":"CA Cancer J Clin"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03620-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03620-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03620-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:48:10Z","timestamp":1781624890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03620-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3620"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03620-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving animals were authorized by the Italian Ministry of Health and performed in agreement with the authorized protocol and ethical standards, according to the Declaration of Helsinki. Studies involving human participants were approved by the Ethics Committee of the Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy. A written informed consent was obtained from each patient prior to his\/her enrollment into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We declare that this manuscript is original, has not been published previously, and is not under consideration for publication in any other journal. The manuscript has been read and approved by all Authors, and no individuals who meet the criteria for authorship have been omitted. All Authors have agreed upon the order in which their names are listed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following conflict of interest: SEN, GM, RC, GAA, EB are co-founders and\/or holders of Andremacon S.r.l. SEN, GM, RC, GAA, EB, LR are inventors of a patent application related to antibody use. All other authors declare no competing financial or personal interests that could influence the work reported in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}